Business Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd
ISIN : CNE100003YN2
Share Class Description:
SHEZF: Class HTotal Employee Number:
2,150Compare
Compare
Traded in other countries / regions
002399.China09989.Hong KongSHEZF.USA IPO Date
2020-11-05Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.08 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.27 | |||||
Debt-to-EBITDA | 6.6 | |||||
Interest Coverage | 11.17 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.72 | |||||
Beneish M-Score | -2.87 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -8.5 | |||||
3-Year EBITDA Growth Rate | -14.9 | |||||
3-Year EPS without NRI Growth Rate | -17.4 | |||||
3-Year Book Growth Rate | -0.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 43.37 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.46 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.15 | |||||
Quick Ratio | 1.21 | |||||
Cash Ratio | 0.79 | |||||
Days Inventory | 461.9 | |||||
Days Sales Outstanding | 93.41 | |||||
Days Payable | 32.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Payout Ratio | 0.71 | |||||
3-Year Dividend Growth Rate | 92.6 | |||||
Shareholder Yield % | 8.69 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 33.54 | |||||
Operating Margin % | 12.8 | |||||
Net Margin % | 7.03 | |||||
EBITDA Margin % | 9.12 | |||||
FCF Margin % | 26.64 | |||||
OCF Margin % | 28.51 | |||||
ROE % | 3.12 | |||||
ROA % | 2.22 | |||||
ROIC % | 4.67 | |||||
3-Year ROIIC % | 12.02 | |||||
ROC (Joel Greenblatt) % | 6.63 | |||||
ROCE % | 3.79 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 36.73 | |||||
Forward PE Ratio | 5.52 | |||||
PE Ratio without NRI | 27.52 | |||||
Shiller PE Ratio | 27.12 | |||||
Price-to-Owner-Earnings | 79.58 | |||||
PS Ratio | 2.59 | |||||
PB Ratio | 1.15 | |||||
Price-to-Tangible-Book | 1.47 | |||||
Price-to-Free-Cash-Flow | 9.71 | |||||
Price-to-Operating-Cash-Flow | 9.07 | |||||
EV-to-EBIT | 24.95 | |||||
EV-to-EBITDA | 24.95 | |||||
EV-to-Revenue | 2.27 | |||||
EV-to-FCF | 8.53 | |||||
Price-to-GF-Value | 0.85 | |||||
Price-to-Projected-FCF | 1.02 | |||||
Price-to-Median-PS-Value | 0.59 | |||||
Price-to-Graham-Number | 1.34 | |||||
| Price-to-Net-Current-Asset-Value | 2.94 | |||||
Earnings Yield (Greenblatt) % | 4.01 | |||||
FCF Yield % | 11.36 | |||||
Forward Rate of Return (Yacktman) % | -21.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SHEZF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shenzhen Hepalink Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 766.986 | ||
| EPS (TTM) ($) | 0.037 | ||
| Beta | 0.1333 | ||
| 3-Year Sharpe Ratio | -0.79 | ||
| 3-Year Sortino Ratio | -0.78 | ||
| Volatility % | 4.51 | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 0.4696 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0.4696 - 0.4696 | ||
| Shares Outstanding (Mil) | 1,467.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shenzhen Hepalink Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shenzhen Hepalink Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| HKD 0.166040 Cash Dividend | 2026-05-27 | 0.47 (+0.00%) | ||
| HKD 0.271650 Cash Dividend | 2025-05-27 | 0.47 (+0.00%) |
Show
Entries
Shenzhen Hepalink Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Shenzhen Hepalink Pharmaceutical Group Co Ltd(SHEZF)'s stock price today?
The current price of SHEZF is $0.47. The 52 week high of SHEZF is $0.47 and 52 week low is $0.47.
When is next earnings date of Shenzhen Hepalink Pharmaceutical Group Co Ltd(SHEZF)?
The next earnings date of Shenzhen Hepalink Pharmaceutical Group Co Ltd(SHEZF) is .
Does Shenzhen Hepalink Pharmaceutical Group Co Ltd(SHEZF) pay dividends? If so, how much?
Shenzhen Hepalink Pharmaceutical Group Co Ltd(SHEZF) does not pay dividend.
Guru Commentaries on OTCPK:SHEZF
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab | 2023-03-28 |
Articles on Shenzhen Hepalink Pharmaceutical Group Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers